Prevalence and Phenotypes of Age-Related Macular Degeneration in Eyes With High Myopia.
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ therapeutic use
Choroidal Neovascularization
/ epidemiology
Female
Geographic Atrophy
/ epidemiology
Humans
Italy
/ epidemiology
Macular Degeneration
/ drug therapy
Male
Middle Aged
Myopia, Degenerative
/ drug therapy
Phenotype
Prevalence
Retinal Drusen
/ epidemiology
Retrospective Studies
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
26
9
2019
Statut:
ppublish
Résumé
To analyze the frequency and phenotypic variation of AMD in subjects with high myopia (HM), and to describe the clinical course and response to treatment of neovascularization (NV). Patients with HM were identified at five retina tertiary referral centers. Inclusion criteria were myopic patients aged 55 years or more with axial lengths equal or greater than 25.5 mm. A total of 874 eyes from 442 HM subjects older than 55 years were identified and 104 eyes of 54 patients (72 ± 11 years) were included in the study and followed up for 23.5 ± 19.5 months. The estimated AMD frequency in HM subjects over 55 years was 11.9% (95% confidence interval; 9.8%-14.0%). A total of 34 of 104 eyes were diagnosed with drusen, 22 with reticular pseudodrusen (RPD), 28 with both drusen and RPD, and 20 with geographic atrophy. Neovascularization was detected in 52 eyes (50%), and type 1 was the most frequent form (39 eyes, 75%). Overall, NV was treated with 4.6 ± 2.6 anti-VEGF injections. Eyes with treatment-naïve NV at baseline (n = 34) required 3.8 ± 1.5 anti-VEGF injections during the first year of treatment. This exceeded the injection number in the purely myopic population (1.8 to 3.6 injections for the first year). This study provides evidence to suggest that older patients with HM are at a significant risk of the dry and neovascular forms of AMD. NV in eyes with HM and AMD required more injections in the first year compared to NV in HM eyes without AMD.
Identifiants
pubmed: 30938774
pii: 2730241
doi: 10.1167/iovs.18-25534
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM